Monoclonal antibody therapies will be the first drugs permitted to take advantage of alternatives, including advanced lab simulations and artificial intelligence. A pilot framework to phase out the decades-long requirement for animal testing will be rolled out in the coming year, the FDA said.
Monoclonal antibody therapies will be the first drugs permitted to take advantage of alternatives, including advanced lab simulations and artificial intelligence. A pilot framework to phase out the decades-long requirement for animal testing will be rolled out in the coming year, the FDA said.